Liver Toxicities Force Pause on Two Dose Groups of UniQure’s Mid-Stage Fabry Study

The gene therapy uses an AAV vector to restore healthy levels of the alpha-galactosidase enzyme, which is rendered dysfunctional in patients with Fabry disease, leading to the toxic build-up of lipids in cells.